• Something wrong with this record ?

Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

JJ. Paik, J. Vencovský, C. Charles-Schoeman, GC. Wright, RA. Vleugels, AS. Goriounova, PN. Mudd, R. Aggarwal

. 2025 ; 43 (2) : 354-363. [pub] 20240715

Language English Country Italy

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25010144

Dermatomyositis (DM) is a rare and debilitating, systemic, autoimmune disease. While heterogenous in presentation and severity, DM is primarily characterised by a spectrum of skin and muscle disease, which may include proximal muscle weakness and recalcitrant cutaneous eruptions. DM may also be associated with joint pain and stiffness, inflammatory arthritis, dysphagia, fatigue, and calcinosis. The current standard of care for DM includes glucocorticoids, immunosuppressants, and intravenous immunoglobulin (IVIg). Unfortunately, these medications are not uniformly effective and can lead to adverse events, particularly with chronic use, necessitating discontinuation of therapy. Therefore, a substantial unmet need exists for more tailored and efficacious therapies that target DM pathogenesis. Brepocitinib is an oral, once-daily, novel, and specific TYK2/JAK1 inhibitor. Brepocitinib's potent inhibition of TYK2 and JAK1 reduces the signalling of pro-inflammatory cytokines, including IFN-α/β, IL-12, IL-23, and IFNγ, that have been implicated in the pathogenesis of DM. Other JAK inhibitors have been used off-label in both case series and open-label clinical trials in patients with DM; and brepocitinib has demonstrated efficacy in phase 2 clinical trials of several other autoimmune diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, hidradenitis suppurativa, and ulcerative colitis. Therefore, there is a strong scientific and clinical rationale for the utility and potential effectiveness of brepocitinib in the treatment of DM patients. Currently, the safety, tolerability, and efficacy of brepocitinib is being evaluated in the largest (n=225) double-blind placebo-controlled phase 3 trial in DM patients to date (VALOR - NCT0543726).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010144
003      
CZ-PrNML
005      
20250429134539.0
007      
ta
008      
250415s2025 it f 000 0|eng||
009      
AR
024    7_
$a 10.55563/clinexprheumatol/eeglsa $2 doi
035    __
$a (PubMed)39008325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Paik, Julie J $u Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jpaik1@jhmi.edu
245    10
$a Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis / $c JJ. Paik, J. Vencovský, C. Charles-Schoeman, GC. Wright, RA. Vleugels, AS. Goriounova, PN. Mudd, R. Aggarwal
520    9_
$a Dermatomyositis (DM) is a rare and debilitating, systemic, autoimmune disease. While heterogenous in presentation and severity, DM is primarily characterised by a spectrum of skin and muscle disease, which may include proximal muscle weakness and recalcitrant cutaneous eruptions. DM may also be associated with joint pain and stiffness, inflammatory arthritis, dysphagia, fatigue, and calcinosis. The current standard of care for DM includes glucocorticoids, immunosuppressants, and intravenous immunoglobulin (IVIg). Unfortunately, these medications are not uniformly effective and can lead to adverse events, particularly with chronic use, necessitating discontinuation of therapy. Therefore, a substantial unmet need exists for more tailored and efficacious therapies that target DM pathogenesis. Brepocitinib is an oral, once-daily, novel, and specific TYK2/JAK1 inhibitor. Brepocitinib's potent inhibition of TYK2 and JAK1 reduces the signalling of pro-inflammatory cytokines, including IFN-α/β, IL-12, IL-23, and IFNγ, that have been implicated in the pathogenesis of DM. Other JAK inhibitors have been used off-label in both case series and open-label clinical trials in patients with DM; and brepocitinib has demonstrated efficacy in phase 2 clinical trials of several other autoimmune diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, hidradenitis suppurativa, and ulcerative colitis. Therefore, there is a strong scientific and clinical rationale for the utility and potential effectiveness of brepocitinib in the treatment of DM patients. Currently, the safety, tolerability, and efficacy of brepocitinib is being evaluated in the largest (n=225) double-blind placebo-controlled phase 3 trial in DM patients to date (VALOR - NCT0543726).
650    _2
$a lidé $7 D006801
650    12
$a kinasa TYK2 $x antagonisté a inhibitory $7 D053634
650    12
$a Janus kinasa 1 $x antagonisté a inhibitory $7 D053613
650    12
$a dermatomyozitida $x farmakoterapie $x diagnóza $x imunologie $7 D003882
650    12
$a inhibitory proteinkinas $x terapeutické užití $x škodlivé účinky $7 D047428
650    _2
$a výsledek terapie $7 D016896
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a zvířata $7 D000818
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vencovský, Jiri $u Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Charles-Schoeman, Christina $u Division of Rheumatology, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
700    1_
$a Wright, Grace C $u Association of Women in Rheumatology, New York, NY, USA
700    1_
$a Vleugels, Ruth Ann $u Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Goriounova, Alexandra S $u Priovant Therapeutics Inc., New York, NY, USA
700    1_
$a Mudd, Paul N $u Priovant Therapeutics Inc., New York, NY, USA. paul.mudd@priovanttx.com
700    1_
$a Aggarwal, Rohit $u Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
773    0_
$w MED00001116 $t Clinical and experimental rheumatology $x 0392-856X $g Roč. 43, č. 2 (2025), s. 354-363
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39008325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134534 $b ABA008
999    __
$a ok $b bmc $g 2311493 $s 1247225
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 43 $c 2 $d 354-363 $e 20240715 $i 0392-856X $m Clinical and experimental rheumatology $n Clin Exp Rheumatol $x MED00001116
LZP    __
$a Pubmed-20250415
Back

Find record

Citation metrics

Archiving options